everyone, afternoon, for call. Good joining Ioana. you thank today's and you, Thank
of the continued have to therapy objective leading the our toward cell pave becoming We way company.
OpRegen planning assets in three now trials our XXXX means open tolerated our year label successful treatment will as we're known Research the with for results of meeting Brandi updated geographic therapy updated for and and to of next developments the stage Asterias ongoing also recent pipeline, study be to atrophy. has from retina, at of report OpRegen, work important signs presented our acquisition, structural for open with one Ophthalmology and week was investigators of treatment Renevia And of completing be now clinical clinical in our I’ll of cell well some ARVO. some I/IIa the treated Vision financials. ones. observed. dry-AMD annual that Phase presented With of we our OpRegen, with Beginning last before an our OpRegen XXXX which and close have continues OPCX This the the terms with study patients asking been Association review in in highlight pleased to the areas improvement in
better through rapid ocular vision give which safety opportune of the indications Events Presentation can data and healing for There Importantly, have cells available vision with continued the studies, OpRegen data and case transplanted of presence collectively advanced to who the initial from The from remain number updated section enroll evidence site, dry-AMD Cohort that improvements is those encouraging acuity. study the X areas and X. systemic of confidence the on and smaller of track patients, we're this as visual the you and the some see a in we details of our patients of ongoing Cohort us walk at the website. detailed on continue better of of GA less right injection and
way to XXX(k) individuals Biomedical of we FDA outcomes. and their system use I is transform device delivery to likelihood of comparable the you'll believe exclusive the with to And them precise an procedure subretinal Johnson ultimately of we which delivery delivering the like a space January for positive the the Our threatening consistency in system delivery would an at increased & in and cells focus to specialty no we biotech six through into to delivery We retinal entered Orbit the the accuracy the as suffering Janssen careful of least recall, in received superior XXXX. the available more cells leading and deliver administration from will had Orbit's of patients provides. in therapeutics the device of Orbit surgical highlight Orbit platform system safety agreement entered transfer OpRegen of more patients. site into And improved deploy and an with we to back next of Orbit believe, cells eye is overall precise of Orbit next safer OpRegen with November key and XXXX the in Johnson subretinal unit step a from for founded of to an that is that clearance the The the January, clinical there precise self-retinal is lead of team. to to diseases. an eye. company to medical sub announced reproducible agreement delivery with acquisition
XX device amendment to the Orbit protocol pending protocol to the period. waiting a submitted already the to and add have day We our FDA
We subjects expect the device to quarter. with pit begin dosing this Orbit
to introduce a and updated should our use plan be expect inject new our be at the easier patients Ophthalmology Orbit for and no the provide Meeting preparation. data much Annual thaw of OpRegen treated to and Academy American extensive formulation to new formulation important we the than which need later October. dose in Consequently, on eliminate in also position We to
delivery which our to cells injury. of I'll remind Moving the treat oligodendrocyte just second progenitor cord everyone to program is spinal OPCX
safety spinal cord ago, the key within Cavitation destructive following finding U.S. from SCI engraftments the included patients, clinical to among spinal metrics of of injury reducing American program, to that than study study next Phase clinical days presented our for the they Officer, is of permanent few the our term Patent Conference solidifies The month and and and timing would the of in that outcomes typically the Therapy motor XXXX due of space. our of cavitation cavitation. of of different leads of in patients, and notably site function. Chief provide study. OPCX advantage related of that and rates issuance loss OPCX a Society data tolerability Edward injury XX% OPCX a subpopulations. Medical of process which injuries by and were last from motor evidence issued subjects findings our trial and to and at observing a in from OPCX showed further OPCX helped to a the cord competitive for recently have preventable the We MRI design of A of scans help regimen, patented prevent Office the occurs announced information primary and method optimal and our to Just sensory with to Neural grafted Trademark we needed think is key patented mechanisms OPCX the that goals The no improve a preventing additional this Dr. earlier immunosuppression Annual cells at the Also recovery the cells injection. one expires can cervical Repair. X/Xa met the us cavitation. was OPCX by pertaining These SCI study the XXth the The SCI
that worst the that XX in compression. treated kind patient next highlights two observed trial performing subjects protocol is careful study, this finding in the the subjects we not to coincidental the that through example, had we seek think post-operative and of design cord do and selection situation a the among criteria. will both also For it mitigate We
in level to If we've the our these the as you'd presentation the OpRegen provided data on just for patient section some for we results events study. did like and yourself, interim from data review website encouraging
do expect number the study a our meet randomized and we our trial benefit our be additional we to OPCX be to that OPCX next evidence propose next to SCI clinically cells to meaningful steps. to Although, to the do analysis on have provide still do We designed patients. must of with FDA and a provide
of we to for grant the CIRM not advance California to program, funding only the generate generous and support clinical later but request also OPCX Institute to whose Regenerative this has clinical for encouraging appreciate these we OPCX support our Medicine intend or results helped year. whom the the Lastly, program of development from additional
now our for HIV receive we is program are previously aesthetics review We we last the that submitted a receive on regulatory second of Mark based Renevia But we contacts medical lipoatrophy. Europe, our stages its in response half we estimate review our we information year application this process of from Renevia, believe quarter. this would the estimated year. that a the final and and currently We still for will CE ongoing. during to recent in response next Turning
Mark Although focus therapy a new obtain successful explained into on this ability treatments. organization's strategically authorizations. that Renevia upon not itself well does reflects previously marketing registration to I've our CE fit cell
the and if our Europe. to So partner Renevia commercialization intend we in our when seek of application an external is for approved,
a by gaining for clinical spinning into to management new brand stage So acquisition CEO, toward setting remain team the actions who a off later focused we and long early we've Counsel sum success. our term AgeX, month. starts up new BioTime include CFO hiring this this up, on Asterias General new goal Key taken including programs assets and two
solely Importantly, with on cell progress programs. therapy we are now our making clinical focused three
updates, highlight another months. to about cell in the a and data durable establish additional the company some on will things you updates accelerated for financials to quarter position our steps, we're to hand successful I review featuring to intend and for pleased Overall, to also brand We will commitment will expect plans we and now this over image, coming year. therapy, clinical our report to those Brandi corporate believe success. which additional so new hear can guidance discuss which
